Cargando…

Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers

The phosphoinositide 3-kinase (PI3K) pathway is an important regulator of cell proliferation and metabolism. PI3K activation initiates a signal transduction cascade, of which the major effectors are the kinases AKT and mTOR. Aberrant activation of the PI3K/AKT/mTOR pathway is frequently observed in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kandoussi, Ilham, Benherrif, Oussama, Lakhlili, Wiame, Taoufik, Jamal, Ibrahimi, Azeddine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265960/ https://www.ncbi.nlm.nih.gov/pubmed/32514232 http://dx.doi.org/10.5114/wo.2020.93334

Ejemplares similares

Docking analysis of verteporfin with YAP WW domain
por: Kandoussi, Ilham, et al.
Publicado: (2017)

Structure–activity relationships study of mTOR kinase inhibition using QSAR and structure-based drug design approaches
por: Lakhlili, Wiame, et al.
Publicado: (2016)

Determination and validation of mTOR kinase-domain 3D structure by homology modeling
por: Lakhlili, Wiame, et al.
Publicado: (2015)

Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis
por: Arrouchi, Housna, et al.
Publicado: (2019)

Molecular screening and docking analysis of LMTK3and AKT1 combined inhibitors
por: Allam, Loubna, et al.
Publicado: (2018)

A review on PIM kinases in tumors
por: Arrouchi, Housna, et al.
Publicado: (2019)

Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis
por: Hakmi, Mohammed, et al.
Publicado: (2020)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

AKT1 Polymorphism (rs10138227) and Risk of Colorectal Cancer in Moroccan Population: A Case Control Study
por: Allam, Loubna, et al.
Publicado: (2020)

Facing Antitubercular Resistance: Identification of Potential Direct Inhibitors Targeting InhA Enzyme and Generation of 3D-pharmacophore Model by in silico Approach
por: EL Haddoumi, Ghyzlane, et al.
Publicado: (2023)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Molecular docking of potential inhibitors with the mTOR protein
por: Fathima, JH Shazia, et al.
Publicado: (2021)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

MOB kinase activator 1A acts as an oncogene by targeting PI3K/AKT/mTOR in ovarian cancer
por: Lei, Jian, et al.
Publicado: (2023)

Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway
por: Zapevalova, Maria V., et al.
Publicado: (2022)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Selective Non-toxics Inhibitors Targeting DHFR for Tuberculosis and Cancer Therapy: Pharmacophore Generation and Molecular Dynamics Simulation
por: Haddoumi, Ghyzlane EL, et al.
Publicado: (2023)

2D-QSAR and docking study of a series of coumarin derivatives as inhibitors of CDK (anticancer activity) with an application of the molecular docking method
por: Kasmi, Rania, et al.
Publicado: (2020)

Dock7 regulates AKT and mTOR/S6K activity required for the transformed phenotypes and survival of cancer cells
por: Teran, Oriana Y., et al.
Publicado: (2023)

Akt and mTOR in B Cell Activation and Differentiation
por: Limon, Jose J., et al.
Publicado: (2012)

Akt and mTOR mediate programmed necrosis in neurons
por: Liu, Q, et al.
Publicado: (2014)

The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
por: Su, Hengchuan, et al.
Publicado: (2013)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis
por: Ge, Fengmei, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_02psh3jhttcbeae9lqqh0m9hdb